Merck PE Ratio 2010-2022 | MRK

Current and historical p/e ratio for Merck (MRK) from 2010 to 2022. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Merck PE ratio as of September 29, 2022 is 11.48.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Merck PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2022-09-29 86.64 13.27
2022-06-30 90.45 $6.53 13.85
2022-03-31 80.74 $5.59 14.44
2021-12-31 74.76 $5.14 14.54
2021-09-30 72.59 $2.83 25.65
2021-06-30 74.48 $2.19 34.01
2021-03-31 73.20 $2.76 26.52
2020-12-31 77.00 $2.77 27.80
2020-09-30 77.46 $4.52 17.14
2020-06-30 71.69 $4.10 17.49
2020-03-31 70.77 $3.95 17.92
2019-12-31 82.99 $3.81 21.78
2019-09-30 76.29 $3.58 21.31
2019-06-30 75.49 $3.57 21.15
2019-03-31 74.38 $3.17 23.46
2018-12-31 67.88 $2.32 29.26
2018-09-30 62.57 $1.31 47.76
2018-06-30 53.17 $0.56 94.95
2018-03-31 47.35 $0.64 73.98
2017-12-31 48.49 $0.93 52.14
2017-09-30 54.71 $1.67 32.76
2017-06-30 54.37 $2.47 22.01
2017-03-31 53.51 $2.19 24.43
2016-12-31 49.21 $1.98 24.85
2016-09-30 51.78 $2.20 23.54
2016-06-30 47.44 $1.66 28.58
2015-12-31 42.77 $1.56 27.42
2015-09-30 39.65 $3.75 10.57
2015-06-30 45.31 $3.42 13.25
2015-03-31 45.40 $3.86 11.76
2014-12-31 44.50 $4.10 10.85
2014-09-30 46.10 $1.82 25.33
2014-06-30 44.66 $1.89 23.63
2014-03-31 43.50 $1.51 28.81
2013-12-31 38.05 $1.46 26.06
2013-09-30 35.87 $1.66 21.61
2013-06-30 34.68 $1.84 18.85
2013-03-31 32.71 $2.12 15.43
2012-12-31 30.01 $2.16 13.89
2012-09-30 32.73 $2.19 14.95
2012-06-30 30.02 $2.18 13.77
2012-03-31 27.31 $2.25 12.14
2011-12-31 26.52 $2.03 13.07
2011-09-30 22.73 $1.37 16.59
2011-06-30 24.24 $0.93 26.07
2011-03-31 22.44 $0.52 43.15
2010-12-31 24.22 $0.28 86.48
2010-09-30 24.47 $2.81 8.71
2010-06-30 23.01 $3.10 7.42
2010-03-31 24.31 $4.47 5.44
2009-12-31 23.54 $5.11 4.61
2016-03-31 43.22 $3.42 12.64
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $219.838B $48.704B
Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda, Simponi , Januvia and Janumet, Bridion, Isentress, ProQuad, Gardasil, Pneumovax 23, RotaTeq and Belsomra. Merck made its biggest acquisition of Schering-Plough and sold off its Consumer Care business to Bayer. Other key acquisitions include Idenix Pharmaceuticals, Cubist Pharmaceuticals, Rigontec, ArQule and Acceleron Pharma. IMerck spun off products from its Women's Health unit, legacy drugs and biosimilar products into a new publicly traded company called Organon & Co.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $437.390B 16.65
Eli Lilly (LLY) United States $317.719B 40.29
AbbVie (ABBV) United States $255.667B 10.86
Pfizer (PFE) United States $249.357B 7.31
Novo Nordisk (NVO) Denmark $224.849B 29.66
Novartis AG (NVS) Switzerland $168.866B 12.45